Multicenter, Randomized, Double-Blind, Sham Surgery-Controlled Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) to Assess the Efficacy and Safety of Bilateral Intraputaminal (IPu) Delivery in Subjects With Idiopathic Parkinson's Disease
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2016
At a glance
- Drugs CERE 120 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Ceregene
- 20 Oct 2010 Dosing paradigm revised for phase IIb trial (700049522) based on results from this trial, according to Ceregene media release.
- 27 May 2009 Additional results reported in a Ceregene media release.
- 08 Apr 2009 Actual initiation date (1 Nov 2006) and lead investigator (Siffert J) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History